<DOC>
	<DOC>NCT02899962</DOC>
	<brief_summary>A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris. A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel group trial.</brief_summary>
	<brief_title>LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris</brief_title>
	<detailed_description>After an initial 4-week period of once-daily treatment with open-label active LEO 90100 aerosol foam, subjects who qualify for randomisation will continue into a 52-week maintenance treatment period with twice-weekly application of randomised LEO 90100 aerosol foam / LEO 90100 aerosol foam vehicle. If the subject experiences a relapse of psoriasis, the active lesions will be treated for 4 weeks with open-label active LEO 90100 aerosol foam.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>INCLUSION CRITERIA: A clinical diagnosis of psoriasis vulgaris for at least 6 months involving the trunk and/or limbs, amenable to treatment with maximum of 100 g of trial medication per week Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 230% of the body surface area (BSA) A target lesion/target location of at least 3 cm at its longest axis located on the body (i.e., not on the scalp, face or intertriginous areas), scoring at least 1 ('mild') for each of redness, thickness and scaliness, and at least 4 in total by the Investigator's Assessment of Severity of the Target Lesion/Location For subjects participating in HPAaxis testing, furthermore: An extent of psoriasis vulgaris on trunk and/or limbs of disease severity (PGA) of at least 'moderate' affecting between 10 and 30% of the body surface area (BSA) excluding psoriatic lesions of genitals and skin folds at Visit 1. EXCLUSION CRITERIA: Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to Visit 1: etanercept within 4 weeks prior to Visit 1 adalimumab, infliximab within 8 weeks prior to Visit 1 ustekinumab within 16 weeks prior to Visit 1 secukinumab within 12 weeks prior to Visit 1 other products within 4 weeks/5 halflives prior to Visit 1 (whichever is longer) Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants) within 4 weeks prior to Visit 1 Systemic treatment with apremilast within 4 weeks prior to Visit 1 Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to Visit 1 Ultraviolet B (UVB) therapy within 2 weeks prior to Visit 1 Severe and/or extensive scalp psoriasis which, in the opinion of the investigator, requires treatment with potent or superpotent corticosteroids which will be prohibited during the trial For subjects participating in HPAaxis testing, furthermore: Antidepressive medications within 4 weeks prior to Visit 1 or during the trial. Oestrogen therapy (including contraceptives), antidepressant medications and any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>